Teva Pharmaceuticals: Schizophrenia Treatment Without Monitoring Requirements Gains U.S. Market Access
Reading Time: 2 minutes
Teva is increasingly focusing on specialty medications and aims for up to $16.8 billion in revenue by 2026. The FDA approved the drug WELTRUZA for the U.S. market on October 9, 2026. The monthly injection replaces daily pills and does not require medical supervision. From Generic Giant to Focused Innovator Teva Pharmaceuticals (TEVA) (i.) is undergoing a strategic transformation. Under the so-called "Pivot to Growth" strategy, the company is shifting its focus from low-margin generics to innovative specialty medications. This approach...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
